NED Biosystems Revenue and Competitors
Estimated Revenue & Valuation
- NED Biosystems's estimated annual revenue is currently $1.1M per year.
- NED Biosystems's estimated revenue per employee is $155,000
Employee Data
- NED Biosystems has 7 Employees.
- NED Biosystems grew their employee count by -30% last year.
NED Biosystems's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Founder and Executive Chairman | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | CFO & COO | Reveal Email/Phone |
5 | Director Business Operations | Reveal Email/Phone |
NED Biosystems Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is NED Biosystems?
Pursuing No Evidence of Disease NED Biosystems™ is a clinical-stage biotech company developing innovative treatments unlike most available today. We begin with a focus on patients and their families. NED seeks to dramatically improve patients’ outcomes with therapies that lack the toxicity and side effects of today’s treatments, allowing patients a high quality of life. NED has initiated a multi-pronged approach to treating cancer through NED-170, the patented investigational cancer product that affects four key processes that advance all late-stage cancer with an anticipated well-tolerated safety profile. The same four processes that drive cancer are integral to COVID-19. NED has rapidly deployed its translational multi-pronged approach to the development of a prophylactic and treatment for COVID-19. NED-260, an investigational product, is designed to be the first orally administered combination for prophylaxis and treatment against COVID-19.
keywords:N/A
N/A
Total Funding
7
Number of Employees
$1.1M
Revenue (est)
-30%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.4M | 7 | -12% | N/A |
#2 | $0.4M | 7 | -68% | N/A |
#3 | $0.2M | 7 | -79% | $21.8M |
#4 | $1.8M | 7 | 17% | N/A |
#5 | $1.1M | 7 | -36% | N/A |